Rockwell Medical (RMTI) Tops Q2 EPS by 11c, misses on revenue, provides guidance

Rockwell Medical (NASDAQ: RMTI) reported Q2 EPS of $, $0.11 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $18.1 million versus the consensus estimate of $19.97 million.

2023 Guidance:

Net Sales — The Company increased its 2023 net sales guidance from between $78.0 million and $82.0 million to between $82.0 million and $86.0 million. Rockwell Medical anticipates that third quarter 2023 net sales will be between $21.0 million and $23.0 million.
Gross Profit — The Company is increasing its 2023 gross profit guidance from between $7.0 million and $9.0 million to between $8.0 million and $10.0 million.
Profitability — Since Rockwell Medical announced its updated business strategy in November 2022, the Company provided guidance that it expected to achieve profitability in 2024. Rockwell Medical is updating its guidance on profitability and now expects the Company to be profitable in the fourth quarter 2023 and going forward.

For earnings history and earnings-related data on Rockwell Medical (RMTI) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits